Chest
Clinical Investigations: AsthmaBronchial Constriction and Inhaled Colistin in Cystic Fibrosis
Section snippets
Materials and Methods
This study was a prospective, placebo-controlled clinical trial with a crossover design. The aim of the study was to recruit 24 subjects from the Cystic Fibrosis Clinic at the Hospital for Sick Children (HSC). The medical records of CF patients between 5 and 18 years of age who were able to perform technically acceptable spirometry21 and could use a nebulizer with a mouthpiece were reviewed. The selection criteria were based on a previously published study22 in which the subjects were separated
Results
Twenty-three patients were enrolled into the study, and 20 patients completed it (HR group, 12 patients 8 to 18 years of age; LR group, 8 patients 8 to 17 years of age). The LR group lost three patients due to incomplete visits. One patient did not return for scheduled visit 2, and there was difficulty in rebooking during the appropriate time period. Two patients had exacerbations between visits with a baseline FEV1 > 15% lower on visit 2, which excluded them from continuing. None of the three
Discussion
The results indicate that a certain degree of bronchoconstriction following the inhalation of an aerosol is common, irrespective of the agent inhaled. However, for those patients with demonstrated airway lability (ie, the HR group), the fall in FEV1 was greater if the agent being inhaled was colistin. These differences were not apparent in the LR group. The degree of fall in FEV1 was higher than that found in the study by Cunningham et al,17 where 95% of the subjects were regularly receiving
References (29)
- et al.
Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization withPseudomonas aeruginosa
J Pediatr
(1990) - et al.
Nebulized colomycin for early Pseudomonas colonization in cystic fibrosis [letter]
Lancet
(1985) - et al.
Nebulized colistin causes chest tightness in adults with cystic fibrosis
Respir Med
(1994) - et al.
Evaluation of bronchial constriction in cystic fibrosis children after inhaling two different preparations of tobramycin
Chest
(2002) - et al.
Nebulizer choice for treatment of cystic fibrosis patients with inhaled colistin
Chest
(2001) - et al.
A comparison of the availability of tobramycin for inhalation from vented versus unvented nebulizers
Chest
(1998) - et al.
A comparison of pulmonary availability between Ventolin (albuterol) nebules and Ventolin (albuterol) respirator solution
Chest
(1997) - et al.
Safety of aerosolized tobramycin administration for 3 months to patients with cystic fibrosis
Pediatr Pulmonol
(1989) - et al.
Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation
Transplantation
(1997) - et al.
Nebulization and anti-Pseudomonas aeruginosaactivity of colistin
Eur Respir J
(1997)
A reassessment of thein vitroactivity of colistin sulphomethate sodium
J Antimicrob Chemother
Colistin inhalation therapy in cystic fibrosis patients with chronicPseudomonas aeruginosalung infection
J Antimicrob Chemother
Toxicity of colistin in cystic fibrosis patients
DICP
Antibiotic treatment of initial colonization withPseudomonas aeruginosapostpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
Pediatr Pulmonol
Cited by (68)
Pharmacokinetics and pharmacodynamics of peptide antibiotics
2022, Advanced Drug Delivery ReviewsCitation Excerpt :Neurotoxicity involving both the central and peripheral nervous systems [168,169] is another major adverse effect of polymyxins which may lead to respiratory failure and apnea [152,153,170–174]. Other adverse effects associated with polymyxin use include skin hyperpigmentation [175–177], pulmonary toxicity [178–181 182] and immunotoxicity [183]. Given the narrow therapeutic window of polymyxins, therapeutic drug monitoring (TDM) and adaptive feedback control (AFC) have been recommended to individualize dosing of polymyxin B and CMS and reduce their toxicity in patients [114,184,185].
Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis
2019, Journal of Cystic FibrosisThe utility of drug reaction assessment trials for inhaled therapies in patients with chronic lung diseases
2018, Respiratory MedicineCitation Excerpt :This study is important as DRAs are recommended for inhaled products despite a poor evidence base and have significant resource implications, requiring physiotherapy assessment and monitoring [7–9]. Previous studies have assessed tolerance and bronchoconstriction in patient groups, but these have normally been within the context of long term inhaled therapy trials or small studies in induced sputum [6,11–13]. This is the first study to assess the utility and outcome of such an assessment in a large cohort including different products and underlying diseases.
Cystic Fibrosis
2015, Murray and Nadel's Textbook of Respiratory Medicine: Volume 1,2, Sixth EditionAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
2023, Cochrane Database of Systematic Reviews
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (e-mail: [email protected]).
The nebulizers were generously provided by Pari Respiratory Equipment, and the colistin was provided by Parke Davis Canada. The study was supported in part by the Canadian Cystic Fibrosis Foundation, and no author had any financial relationship with either Pari Respiratory Equipment Inc. or Parke Davis Canada.